Skip to content
OpenCapital
Get started

Tarsus Pharmaceuticals, Inc. TARS Remainder of Fiscal Year 2025

Remainder of Fiscal Year 2025 at other companies

Bausch + Lomb logo
Bausch + LombBLCO
——

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%—
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s remainder of fiscal year 2025.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s remainder of fiscal year 2025?
Tarsus Pharmaceuticals, Inc. (TARS) reported remainder of fiscal year 2025 of $721K in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s remainder of fiscal year 2025 changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s remainder of fiscal year 2025 decreased by 0.0% year-over-year, from $721K to $721K.